Home › Companies › RLMD

Relmada Therapeutics

Market cap $321M 106.7M shares (10-Q, Nov 10, 2026) × $3.01 close Nov 17, 2026

Most recent annual filing: 2026-03-19

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. NDV-01 readout2026NDV-01 readout, 2026, material
  2. NDV-01 IND filingyear-end 2026NDV-01 IND filing, year-end 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Discontinued (2)

Capital (as filed)

Cash
$5.7M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$196M Sep 30, 2026
Operating cash flow
−$12.6M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$202M cash per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (3)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (3 calls)

Every verdict Biotech Distilled has published on Relmada Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Relmada Therapeutics (RLMD) — Scientific Deep Dive for NDV-01 and Sepranolone NDV-01 has de-risked biology and a genuine office-based delivery advantage over INLEXZO, but pivotal-population data does not yet exist and the team's late-stage track record is poor; the year-end 2026 Cohort 2A readout is the gate to a potential upgrade.
  2. Watch UPDATE: Relmada Therapeutics (RLMD) - The Catalyst Just Moved Right Phase 3 initiation slipped from mid-2026 to upon IND clearance due to CMC bottleneck, pushing the first efficacy readout to 2027–2028; the thesis is stretched but not broken, and the Watch stance is maintained pending the IND filing.
  3. Watch UPDATE: Relmada Therapeutics (RLMD) - The First Cracks in a Perfect Record CMC appears on track for a year-end IND, but first progressions to muscle-invasive disease, a drifting BCG-unresponsive 12-month CR, a pivoting IR cohort, and contradictory funding language keep the Watch stance intact with no reason to hurry.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (25)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 28, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

12 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)